CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING
Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic.Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomiti...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2017-11-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/2175 |
| _version_ | 1797841408829161472 |
|---|---|
| author | I. A. Koroleva M. V. Kopp E. M. Lipaeva |
| author_facet | I. A. Koroleva M. V. Kopp E. M. Lipaeva |
| author_sort | I. A. Koroleva |
| collection | DOAJ |
| description | Chemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic.Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomiting in patients with breast cancer receiving chemotherapy regimen AC.Materials and methods: 82 female patients with breast cancer received adjuvant chemotherapy regimen AC: doxorubicin 60 mg/ m2, cyclophosphamide 600 mg/m2 in day 1, each 21 day 4 cycle. Patients received an triple-therapy regimen (aprepitant 125 mg p.o. in day 1, 80 mg in days 2 and 3, ondansetron 8 mg i.v. in 1 day, dexamethasone 12 mg i.v.in 1 day, then to 8 mg/day p.o. in days 2–4) for prevention of nausea and vomiting.Results: During the first cycle of chemotherapy in acute phase (0-24 hours from the start of chemotherapy) complete control of nausea and vomiting was achieved at 72 (87.8%) patients. During delayed phase (25-120 hours from the start of chemotherapy) complete control achieved at 56 (68.3%)patients . 57.3% of patients had complete control of nausea and vomiting during all 4 cycles.Conclusion: Adequate regimen for prevention of nausea and vomiting is combination of NK1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone. Triple-therapy regimen allows more than half of the patients undergo 4 cycles of AC without nausea and vomiting. |
| first_indexed | 2024-04-09T16:30:21Z |
| format | Article |
| id | doaj.art-12a4c0948764482b895704206ec3bbfa |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:30:21Z |
| publishDate | 2017-11-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-12a4c0948764482b895704206ec3bbfa2023-04-23T06:57:07ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902017-11-0101411211710.21518/2079-701X-2017-14-112-1172151CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITINGI. A. Koroleva0M. V. Kopp1E. M. Lipaeva2Medical University ReavizMedical University ReavizSamara regional clinical oncology dispensaryChemotherapy regimen AС (doxorubicin and cyclophosphamide) is the most often used in adjuvant chemotherapy of breast cancer. AC regimen is high emetogenic.Objective – to evaluate the effectiveness of the combination of aprepitant, ondansetron and dexamethasone for the prevention of nausea and vomiting in patients with breast cancer receiving chemotherapy regimen AC.Materials and methods: 82 female patients with breast cancer received adjuvant chemotherapy regimen AC: doxorubicin 60 mg/ m2, cyclophosphamide 600 mg/m2 in day 1, each 21 day 4 cycle. Patients received an triple-therapy regimen (aprepitant 125 mg p.o. in day 1, 80 mg in days 2 and 3, ondansetron 8 mg i.v. in 1 day, dexamethasone 12 mg i.v.in 1 day, then to 8 mg/day p.o. in days 2–4) for prevention of nausea and vomiting.Results: During the first cycle of chemotherapy in acute phase (0-24 hours from the start of chemotherapy) complete control of nausea and vomiting was achieved at 72 (87.8%) patients. During delayed phase (25-120 hours from the start of chemotherapy) complete control achieved at 56 (68.3%)patients . 57.3% of patients had complete control of nausea and vomiting during all 4 cycles.Conclusion: Adequate regimen for prevention of nausea and vomiting is combination of NK1 receptor antagonist, 5-HT3 receptor antagonist and dexamethasone. Triple-therapy regimen allows more than half of the patients undergo 4 cycles of AC without nausea and vomiting.https://www.med-sovet.pro/jour/article/view/2175breast cancerchemotherapy regimen (doxorubicin and cyclophosphamide)aprepitant |
| spellingShingle | I. A. Koroleva M. V. Kopp E. M. Lipaeva CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING Медицинский совет breast cancer chemotherapy regimen (doxorubicin and cyclophosphamide) aprepitant |
| title | CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING |
| title_full | CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING |
| title_fullStr | CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING |
| title_full_unstemmed | CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING |
| title_short | CHEMOTHERAPY REGIMEN AC (DOXORUBICIN AND CYCLOPHOSPHAMIDE) IN BREAST CANCER – PREVENTION OF NAUSEA AND VOMITING |
| title_sort | chemotherapy regimen ac doxorubicin and cyclophosphamide in breast cancer prevention of nausea and vomiting |
| topic | breast cancer chemotherapy regimen (doxorubicin and cyclophosphamide) aprepitant |
| url | https://www.med-sovet.pro/jour/article/view/2175 |
| work_keys_str_mv | AT iakoroleva chemotherapyregimenacdoxorubicinandcyclophosphamideinbreastcancerpreventionofnauseaandvomiting AT mvkopp chemotherapyregimenacdoxorubicinandcyclophosphamideinbreastcancerpreventionofnauseaandvomiting AT emlipaeva chemotherapyregimenacdoxorubicinandcyclophosphamideinbreastcancerpreventionofnauseaandvomiting |